Revision as of 14:12, 21 February 2025

Induced Pluripotent Stem Cell

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka and his team in 2006, who discovered that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.

History

The concept of reprogramming adult cells to a pluripotent state was first demonstrated in 2006 by Shinya Yamanaka and Kazutoshi Takahashi. They used mouse fibroblasts and introduced four transcription factors: Oct4, Sox2, Klf4, and c-Myc, collectively known as the Yamanaka factors. This groundbreaking discovery earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012.

Methodology

File:Dedifferentiation Methods (2010) - Bischoff, Steven R.tif

Methods of dedifferentiation

The process of creating iPSCs involves the introduction of specific genes into somatic cells. These genes are typically delivered using viral vectors, such as retroviruses or lentiviruses, which integrate into the host cell's genome. Once inside, these genes reprogram the somatic cells to a pluripotent state, similar to that of embryonic stem cells.

Characteristics

iPSCs share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for regenerative medicine, disease modeling, and drug discovery.

Applications

iPSCs have numerous applications in the field of medicine and research. They can be used to model diseases, allowing researchers to study the progression and potential treatments for various conditions. Additionally, iPSCs hold promise for regenerative medicine, where they can be used to generate healthy cells to replace damaged or diseased tissues.

Challenges

Despite their potential, iPSCs face several challenges. One major concern is the risk of tumorigenicity, as the reprogramming process can lead to genetic mutations. Additionally, the use of viral vectors poses a risk of insertional mutagenesis. Researchers are actively working on developing safer and more efficient methods of generating iPSCs.

Future Directions

The future of iPSC research is promising, with ongoing efforts to improve the safety and efficiency of reprogramming techniques. Advances in gene editing technologies, such as CRISPR-Cas9, offer potential solutions to overcome current challenges. Furthermore, the development of non-integrating delivery methods for reprogramming factors is a key area of focus.

Related Pages

@@ Line 1: / Line 1: @@
-{{Short description|Stem cells generated from adult cells}}
+= Induced Pluripotent Stem Cell =
-{{Use dmy dates|date=October 2023}}
-'''Induced pluripotent stem cells''' ('''iPSCs''') are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was pioneered by [[Shinya Yamanaka]] and his team in 2006, for which he was awarded the [[Nobel Prize in Physiology or Medicine]] in 2012. This breakthrough has significant implications for regenerative medicine, disease modeling, and drug discovery.
+[[File:Human_induced_pluripotent_stem_cell_colony_(51816035910).jpg|thumb|right|Human induced pluripotent stem cell colony]]
-==History==
+Induced pluripotent stem cells (iPSCs) are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was pioneered by [[Shinya Yamanaka]] and his team in 2006, who discovered that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
-The concept of reprogramming adult cells to a pluripotent state was first demonstrated by Yamanaka and his colleagues, who introduced four specific genes encoding transcription factors into adult [[fibroblasts]]. These factors, known as the "Yamanaka factors," include [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]]. The introduction of these factors reprograms the adult cells into a pluripotent state, similar to that of [[embryonic stem cells]].
-==Characteristics==
+== History ==
-[[File:Stem cell diagram.svg|thumb|right|Diagram of stem cell differentiation.]]
-Induced pluripotent stem cells share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for studying development and disease.
-===Pluripotency===
+[[File:Production_of_iPSC_Timeline.png|thumb|left|Timeline of iPSC production]]
-Pluripotency refers to the ability of a stem cell to differentiate into any cell type of the body. iPSCs exhibit this property, making them a powerful tool for regenerative medicine. They can be used to generate [[neurons]], [[cardiomyocytes]], [[hepatocytes]], and many other cell types.
-===Self-renewal===
+The concept of reprogramming adult cells to a pluripotent state was first demonstrated in 2006 by Shinya Yamanaka and Kazutoshi Takahashi. They used mouse fibroblasts and introduced four transcription factors: [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]], collectively known as the Yamanaka factors. This groundbreaking discovery earned Yamanaka the [[Nobel Prize in Physiology or Medicine]] in 2012.
-Like embryonic stem cells, iPSCs have the ability to self-renew indefinitely in culture. This property allows for the generation of large quantities of cells for research and therapeutic purposes.
-==Applications==
+== Methodology ==
-[[File:Stem cell research.jpg|thumb|left|Stem cell research in a laboratory setting.]]
-The ability to generate patient-specific iPSCs has opened new avenues in personalized medicine. iPSCs can be used to model diseases, screen drugs, and potentially provide autologous cell therapies.
-===Disease Modeling===
+[[File:Dedifferentiation_Methods_(2010)_-_Bischoff,_Steven_R.tif|thumb|right|Methods of dedifferentiation]]
-By generating iPSCs from patients with specific genetic disorders, researchers can create disease models in vitro. These models help in understanding the pathophysiology of diseases and in identifying potential therapeutic targets.
-===Drug Discovery===
+The process of creating iPSCs involves the introduction of specific genes into somatic cells. These genes are typically delivered using viral vectors, such as retroviruses or lentiviruses, which integrate into the host cell's genome. Once inside, these genes reprogram the somatic cells to a pluripotent state, similar to that of embryonic stem cells.
-iPSCs provide a platform for high-throughput drug screening. By testing compounds on iPSC-derived cells, researchers can identify drugs that may be effective in treating specific diseases.
-===Regenerative Medicine===
+== Characteristics ==
-The potential to generate patient-specific cells for transplantation offers a promising avenue for regenerative medicine. iPSCs could be used to replace damaged tissues in conditions such as [[Parkinson's disease]], [[diabetes]], and [[heart disease]].
-==Challenges==
+iPSCs share many characteristics with [[embryonic stem cells]], including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for regenerative medicine, disease modeling, and drug discovery.
-Despite their potential, iPSCs face several challenges. The reprogramming process can introduce genetic and epigenetic abnormalities. Additionally, the use of oncogenes like c-Myc raises concerns about tumorigenicity.
-==Ethical Considerations==
+== Applications ==
-The use of iPSCs circumvents many ethical issues associated with embryonic stem cells, as they do not require the destruction of embryos. However, ethical considerations regarding genetic manipulation and potential clinical applications remain.
-==Related pages==
+[[File:Three_germ_line_cells_differentiated_from_iPSCs.png|thumb|left|Three germ line cells differentiated from iPSCs]]
-* [[Stem cell]]
+iPSCs have numerous applications in the field of medicine and research. They can be used to model diseases, allowing researchers to study the progression and potential treatments for various conditions. Additionally, iPSCs hold promise for regenerative medicine, where they can be used to generate healthy cells to replace damaged or diseased tissues.
+== Challenges ==
+Despite their potential, iPSCs face several challenges. One major concern is the risk of tumorigenicity, as the reprogramming process can lead to genetic mutations. Additionally, the use of viral vectors poses a risk of insertional mutagenesis. Researchers are actively working on developing safer and more efficient methods of generating iPSCs.
+== Future Directions ==
+[[File:Induction_of_iPS_cells.svg|thumb|right|Induction of iPS cells]]
+The future of iPSC research is promising, with ongoing efforts to improve the safety and efficiency of reprogramming techniques. Advances in gene editing technologies, such as [[CRISPR-Cas9]], offer potential solutions to overcome current challenges. Furthermore, the development of non-integrating delivery methods for reprogramming factors is a key area of focus.
+== Related Pages ==
+* [[Pluripotent stem cell]]
 * [[Embryonic stem cell]]
+* [[Shinya Yamanaka]]
 * [[Regenerative medicine]]
-* [[Shinya Yamanaka]]
 [[Category:Stem cells]]
 [[Category:Regenerative medicine]]

Induced pluripotent stem cell: Difference between revisions